All In Biotech

Drug Trial Radar · NCT06611371

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

A Phase I/II, Observer-Blind, Randomized, Placebo-Controlled, Dose-Selection Study to Assess the Safety, Tolerability, and Immunogenicity of Hexavalent Group B Streptococcus Conjugate Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age (WOCBA) in the US and South Africa.

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Actual

Start

Nov 12, 2024

Primary completion

Aug 26, 2025

Study completion Feb 2026

Sponsor

Lead sponsor
Inventprise Inc.Industry
Sponsor type
Industry
Collaborators
PATH
First posted
Sep 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To assess the safety and tolerability of IVT GBS-06 vaccine administered as a single-dose regimen, at three dosage levels in healthy, non-pregnant, adult women of childbearing age (WOCBA).

Conditions

  • Group B Streptococcal Infections

Interventions

  • IVT GBS-06Biological

    Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.

  • PlaceboBiological

    0.9% sodium chloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety -percentage of participants reporting immediate AE within 30 minutes of vaccinationTime frame: 30 minutes after vaccination
  2. Safety - percentage of participants reporting solicited local adverse events (AEs) within 7 days of vaccinationTime frame: Day 1 - Day 7 after vaccination
  3. Safety- percentage of participants reporting solicited systemic AEs within 7 days following study vaccination (fever, fatigue, headache, chills, myalgia, arthralgia, and nausea/vomiting)Time frame: Day 1 - Day 7 after vaccination
  4. Safety - percentage of participants reporting unsolicited AEs within 28 days following study vaccinationTime frame: Day 1 - Day 28 after vaccination
  5. Safety - percentage of participants with clinically significant laboratory abnormalities within 7 days following study vaccinationTime frame: Day 1 - Day 7 after vaccination
  6. Safety - percentage of participants reporting medically attended adverse events (MAAEs)Time frame: From Day 1 vaccination through the end of study
  7. Safety - percentage of participants reporting serious adverse events (SAEs)Time frame: From Day 1 vaccination through the end of study

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • NYU Grossman School of Medicine

    New York, New York

  • Wits Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), University of the Witwatersrand

    Johannesburg, Gauteng, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.